Randy Christopher Bowen, Soto Hansell, Vishal Raval, Jacquelyn M Davanzo, Arun D Singh
{"title":"葡萄膜黑色素瘤:拒绝治疗。","authors":"Randy Christopher Bowen, Soto Hansell, Vishal Raval, Jacquelyn M Davanzo, Arun D Singh","doi":"10.1159/000515559","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to explore factors for refusing treatment in patients diagnosed with uveal melanoma and their subsequent clinical course.</p><p><strong>Methods: </strong>This study included patients with uveal melanoma who refused standard of care treatment. Patient-reported reasons and pre-existing mental health diagnoses were assessed. The sociodemographic profile was compared with the controls. Ocular survival, metastasis-free survival (MFS), and overall survival (OS) were calculated.</p><p><strong>Results: </strong>Nine patients with uveal melanoma declined ocular treatment (plaque brachytherapy, <i>n</i> = 7 [78%]; enucleation, <i>n</i> = 2 [22%]). The choroidal melanomas were small (<i>n</i> = 1 [11%]), medium (<i>n</i> = 5 [56%]), and large (<i>n</i> = 3 [33%]) in size (COMS criteria). The sociodemographic profile of the study patients was not different from those that accepted treatment. One patient (11%) had pre-existing mental health diagnosis. Five patients (56%) eventually accepted treatment following an average delay of 19 months (range: 4-55 months) due to neovascular glaucoma or severe vision loss. MFS could not be ascertained, and OS was 67% (6/9) at 4.2 years of follow-up (mean).</p><p><strong>Conclusions: </strong>Refusal of initial recommended treatment is associated with poor ocular survival. The small sample size did not allow for an evaluation of the impact on survival.</p>","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531830/pdf/oop-0007-0361.pdf","citationCount":"3","resultStr":"{\"title\":\"Uveal Melanoma: Refusal of Treatment.\",\"authors\":\"Randy Christopher Bowen, Soto Hansell, Vishal Raval, Jacquelyn M Davanzo, Arun D Singh\",\"doi\":\"10.1159/000515559\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>This study aimed to explore factors for refusing treatment in patients diagnosed with uveal melanoma and their subsequent clinical course.</p><p><strong>Methods: </strong>This study included patients with uveal melanoma who refused standard of care treatment. Patient-reported reasons and pre-existing mental health diagnoses were assessed. The sociodemographic profile was compared with the controls. Ocular survival, metastasis-free survival (MFS), and overall survival (OS) were calculated.</p><p><strong>Results: </strong>Nine patients with uveal melanoma declined ocular treatment (plaque brachytherapy, <i>n</i> = 7 [78%]; enucleation, <i>n</i> = 2 [22%]). The choroidal melanomas were small (<i>n</i> = 1 [11%]), medium (<i>n</i> = 5 [56%]), and large (<i>n</i> = 3 [33%]) in size (COMS criteria). The sociodemographic profile of the study patients was not different from those that accepted treatment. One patient (11%) had pre-existing mental health diagnosis. Five patients (56%) eventually accepted treatment following an average delay of 19 months (range: 4-55 months) due to neovascular glaucoma or severe vision loss. MFS could not be ascertained, and OS was 67% (6/9) at 4.2 years of follow-up (mean).</p><p><strong>Conclusions: </strong>Refusal of initial recommended treatment is associated with poor ocular survival. The small sample size did not allow for an evaluation of the impact on survival.</p>\",\"PeriodicalId\":19434,\"journal\":{\"name\":\"Ocular Oncology and Pathology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2021-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531830/pdf/oop-0007-0361.pdf\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ocular Oncology and Pathology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000515559\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/8/27 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ocular Oncology and Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000515559","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/8/27 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
Purpose: This study aimed to explore factors for refusing treatment in patients diagnosed with uveal melanoma and their subsequent clinical course.
Methods: This study included patients with uveal melanoma who refused standard of care treatment. Patient-reported reasons and pre-existing mental health diagnoses were assessed. The sociodemographic profile was compared with the controls. Ocular survival, metastasis-free survival (MFS), and overall survival (OS) were calculated.
Results: Nine patients with uveal melanoma declined ocular treatment (plaque brachytherapy, n = 7 [78%]; enucleation, n = 2 [22%]). The choroidal melanomas were small (n = 1 [11%]), medium (n = 5 [56%]), and large (n = 3 [33%]) in size (COMS criteria). The sociodemographic profile of the study patients was not different from those that accepted treatment. One patient (11%) had pre-existing mental health diagnosis. Five patients (56%) eventually accepted treatment following an average delay of 19 months (range: 4-55 months) due to neovascular glaucoma or severe vision loss. MFS could not be ascertained, and OS was 67% (6/9) at 4.2 years of follow-up (mean).
Conclusions: Refusal of initial recommended treatment is associated with poor ocular survival. The small sample size did not allow for an evaluation of the impact on survival.